OncoMatch/Clinical Trials/NCT07020806
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Is NCT07020806 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G for metastatic lobular breast carcinoma.
Treatment: [68Ga]Ga DOTA-5G — This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1000 cells/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL
Kidney function
eGFR >60 mL/min/1.73m*2
Liver function
AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN
Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL. Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR >60 mL/min/1.73m*2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify